Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Newcastle University

- PMLiVE

J&J’s subcutaneous Tremfya shows promise in phase 3 Crohn’s disease study

Inflammatory bowel disease affects approximately four million people in Europe

- PMLiVE

AbbVie gains rights to FutureGen’s inflammatory bowel disease candidate in deal worth $1.7bn

The agreement gives AbbVie exclusive global rights to the TL1A-targeting monoclonal antibody

- PMLiVE

Researchers identify new major cause of inflammatory bowel disease

Crohn’s disease and ulcerative colitis affected more than 500,000 people in the UK in 2022

- PMLiVE

New study aims to identify IBD biomarkers for personalised medicine

The chronic gastrointestinal condition affects more than 540,000 people in the UK

- PMLiVE

Eli Lilly shares positive late-stage results for mirikizumab in Crohn’s disease

Nearly one in every 100 people in the US are diagnosed with inflammatory bowel disease

- PMLiVE

Takeda’s subcutaneous Entyvio approved by FDA as Crohn’s disease maintenance therapy

Inflammatory bowel disease affects around ten million people worldwide

- PMLiVE

Single genetic test could replace current standard for diagnosing rare developmental disorders

The single genetic test could potentially replace the current standard and reduce costs for the NHS

- PMLiVE

AbbVie and Parvus Therapeutics collaborate to develop treatments for inflammatory bowel disease

Both companies will utilise Parvus’ Navacim Treg immune tolerisation platform technology

- PMLiVE

Researchers develop screening tool to investigate mechanisms behind multiple diseases

The technique will assess genetic changes in cells behind cancer, autoimmunity and neurodegeneration

- PMLiVE

Researchers uncover role of inherited genetic variants in rare blood cancer

There are around 4,000 cases of myeloproliferative neoplasms in the UK each year

- PMLiVE

Study identifies hundreds of priority targets for cancer drug discovery

Researchers identified 370 priority drug candidates across 27 types of cancer

- PMLiVE

Eli Lilly’s Omvoh granted FDA approval for ulcerative colitis

Inflammatory bowel disease is estimated to affect nearly one in every 100 people in the US

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links